Ambulero

Executive Summary

Ambulero is a regenerative cell and gene therapy company spun out of the University of Miami in 2020, focused on developing first-in-class therapies for vascular diseases and non-healing wounds. Its proprietary platform engineers cells and vectors to deliver E-selectin, a molecule that promotes tissue repair and angiogenesis. The company's approach addresses significant unmet medical needs in chronic wounds and peripheral artery disease, leveraging a novel mechanism to enhance vascular regeneration. As a private, early-stage biotech, Ambulero has yet to disclose funding rounds or pipeline specifics, but its technology holds promise for patients with limited treatment options. The company's progress will depend on successful preclinical validation, regulatory interactions, and securing partnerships or financing to advance toward clinical trials. Given its innovative approach and focus on regenerative medicine, Ambulero represents a high-risk, high-reward opportunity in the gene therapy space.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Program in Non-Healing Wounds40% success
• Q2 2026Preclinical Proof-of-Concept Data Presentation70% success
• Q3 2026Series A Financing Round Closure50% success